We are looking for a motivated and enthusiastic Senior Flow Cytometry Technician to join the Flow Cytometry Facility within the School of the Biological Sciences, based in the Department of Pathology at the University of Cambridge.
This is an exciting opportunity to work in a small, supportive team (currently two staff members) at the heart of a vibrant, multidisciplinary research environment.
We're seeking a Policy Officer to join our Policy and Evidence team starting from 1 November 2026. This is an exciting opportunity for someone with strong skills in researching, interpreting, and analysing data, and a genuine curiosity about what evidence can reveal, to help drive impactful policy work. As Policy Officer, you will also play a central role in the smooth running of the Policy and Evidence team, while also contributing to the development of policy positions and evidence-based communications.
Established in 2005, the DLRC Group has developed a deserved reputation for being a leading consultancy, with a wealth of regulatory and scientific knowledge and considerable experience in both leadership and management. The company has recently expanded to include affiliates based in Germany and the US.
EMBL-EBI and Wellcome Trust Sanger Institute share the Wellcome Genome Campus. This proximity fosters close collaborations and contributes to an international and vibrant campus environment. Researchers are supported by easy access to scientific expertise, well-equipped facilities and an active seminar programme.
The EMBL-EBI–Sanger Postdoctoral (ESPOD) Programme builds on the strong collaborative relationship between the two institutes, offering projects which combine experimental (wet lab) and computational approaches.
At Cancer Research UK, we exist to beat cancer.
We have an exciting opportunity at Cancer Research Horizons for a skilled Principal scientist to join the Joint AstraZeneca-Cancer Research Horizons Functional Genomics Centre based in Cambridge.
About Iso
Isomorphic Labs (IsoLabs) was launched in 2021 to advance human health by building on and beyond the Nobel-winning AlphaFold system. Since then, our interdisciplinary team of drug discovery experts and machine learning specialists has built powerful new predictive and generative AI models that accelerate scientific discovery at digital speed.
Offers UK academic, biotech and biopharma researchers direct access to specialist project support, 10x Genomics Chromium Single Cell-based workflows, sequencing infrastructure and bioinformatics expertise
Pioneer Group has announced the launch of new regional accelerator programmes designed to support early-stage life science and tech companies accelerate their journey to market.
Pioneer delivers the most comprehensive suite of accelerator and venture building activity across the UK and Ireland, helping founders to transfer cutting-edge discovery into visionary ventures that scale. To date, Pioneer has supported more than 350 entrepreneurs and funded over 195 companies, which have collectively raised £830 million in investment.
About the Role
Scendea is seeking a highly motivated individual to join our global team as a full-time Principal Consultant (CMC, small molecules experience). The ideal candidate will have a proven track record in CMC for small molecule drug development, with expertise in process development, scale-up, regulatory submissions, and the pre-approval life cycle management of small molecule products. This is a hybrid position, affiliated to either of our UK or Australia offices, with a requirement to work in the office a minimum of one day per month.